Differential effect of interleukin-10 on hepatocyte apoptosis. 2005

Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, México, D.F. México. marsantiagolom@yahoo.com.mx

Current data suggests that hepatocyte apoptosis is an essential feature contributing to several chronic liver diseases. It has been shown that IL-10 has diverse and potentially pleiotropic actions that suggest that it may have a direct effect on apoptosis. It has been established that NF-kappaB activation is essential to protect hepatocytes from apoptosis. The purpose of the present work is to evaluate the effect of the anti-inflammatory cytokine, IL-10 on the activation of NF-kappaB in primary cultured rat hepatocytes and hepatoblastoma (HepG2) cell line and explore its consequences on apoptosis. Apoptosis was induced by TNF-alpha and cicloheximide in HepG2 hepatoblastoma cells and by ethanol and a glutathione depletor in primary cultured rat hepatocytes. NF-kappaB activation was determined by EMSA. IL-10 increased ethanol induced apoptosis in primary culture rat hepatocytes (28%). These effects were enhanced when the cells were pre-treated with IL-10 under conditions of oxidative stress (glutathione depletion). The effects of IL-10 on primary cultured hepatocytes were independent of NF-kappaB activation. When apoptosis was induced by cicloheximide and TNF-alpha in hepatoblastoma cells, pretreatment with IL-10 was accompanied by a decrease of 38% in apoptosis. IL-10 did not have any effect on the signaling cascade of apoptosis but caused a significant increase in NF-kappaB activation. When NF-kappaB activation was inhibited by sulfazalazine the decrease in apoptosis was reversed. The present study demonstrates the importance of differential cell marking when trying to characterize the effects of cytokines in their contribution to liver cell apoptosis. The study provides insight into the mechanisms by which IL-10 affects apoptosis through a differential effect on NF-kappaB activation.

UI MeSH Term Description Entries
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012997 Solvents Liquids that dissolve other substances (solutes), generally solids, without any change in chemical composition, as, water containing sugar. (Grant & Hackh's Chemical Dictionary, 5th ed) Solvent

Related Publications

Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
April 2011, European journal of pharmacology,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
January 1998, Oncology research,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
June 2007, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
June 2005, Acta pharmacologica Sinica,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
June 2006, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
January 2015, PloS one,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
April 2002, Chinese medical journal,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
December 1999, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
November 1998, The Journal of veterinary medical science,
Mariana Santiago-Lomelí, and Luis E Gómez-Quiroz, and Víctor M Ortíz-Ortega, and David Kershenobich, and Maria Concepción Gutiérrez-Ruiz
January 2000, International journal of clinical & laboratory research,
Copied contents to your clipboard!